Torna al Registre Simple

 

The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions

dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorKim, Dong-Wan
dc.contributor.authorHollebecque, Antoine
dc.contributor.authorNishino, Kazumi
dc.contributor.authorRha, Sun Young
dc.contributor.authorSchram, Alison
dc.contributor.authorMacarulla, Teresa
dc.date.accessioned2025-02-07T13:12:57Z
dc.date.available2025-02-07T13:12:57Z
dc.date.issued2024
dc.identifier.citationKim DW, Schram AM, Hollebecque A, Nishino K, Macarulla T, Rha SY, et al. The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions. Futur Oncol. 2024;20(16).
dc.identifier.issn1479-6694
dc.identifier.urihttps://hdl.handle.net/11351/12567
dc.descriptionFusió NRG1; Zenocutuzumab; Reclutament
dc.description.sponsorshipMedical writing support was provided by Austin Horton, PhD, of Lumanity Communications Inc., and was funded by Merus NV.
dc.language.isoeng
dc.publisherFuture Medicine
dc.relation.ispartofseriesFuture Oncology;20(16)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectAnticossos monoclonals - Ús terapèutic
dc.subjectMedicaments antineoplàstics - Ús terapèutic
dc.subjectPulmons - Càncer - Tractament
dc.subjectPàncrees - Càncer - Tractament
dc.subjectOncogens
dc.subject.meshAntibodies, Monoclonal, Humanized
dc.subject.meshAntineoplastic Agents, Immunological
dc.subject.mesh/therapeutic use
dc.subject.meshCarcinoma, Non-Small-Cell Lung
dc.subject.meshOncogene Proteins, Fusion
dc.subject.meshCarcinoma, Pancreatic Ductal
dc.titleThe phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.2217/fon-2023-0824
dc.subject.decsanticuerpos monoclonales humanizados
dc.subject.decsinmunoterapia antineoplásica
dc.subject.decs/uso terapéutico
dc.subject.decscarcinoma de pulmón de células no pequeñas
dc.subject.decsproteínas oncogénicas de fusión
dc.subject.decscarcinoma ductal pancreático
dc.relation.publishversionhttps://doi.org/10.2217/fon-2023-0824
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Kim DW] Department of Internal Medicine, Seoul National University College of Medicine & Seoul National University Hospital, Seoul, Republic of Korea. [Schram AM] Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA. [Hollebecque A] Drug Development (DITEP), GI Oncology, Gustave Roussy Cancer Campus, Villejuif, France. [Nishino K] Department of Thoracic Oncology, Osaka International Cancer Institute, Japan. [Macarulla T] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Gastrointestinal and Endocrine Tumor Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Rha SY] Department of Internal Medicine, Yonsei Cancer Center, Yonsei University Health System, Seoul, Republic of Korea
dc.identifier.pmid38348690
dc.identifier.wos001161632800001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Fitxers en aquest element

Portada del document
Name:
phase-i-ii-enrgy-trial-zenocut ...
Grandària:
3.359Mb
Format:
PDF
Description:
The phase I/II eNRGy trial: ...
Visualitza

Aquest element apareix en la col·lecció o col·leccions següent(s)

Torna al Registre Simple